Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus trastuzumab vs lapatinib in HER2-positive metastatic breast cancer after trastuzumab
2005-003926-24Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in HER2-enriched breast cancer (HER2+) comparing Lapatinib + trastuzumab with Lapatinib monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Dec 2005; status: completed.
02
Drugs
lapatinibtrastuzumab
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2005-003926-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003926-24.